[CLSTR]
< Back to all clusters
[BUSINESS] · South Korea · 3 sources

started · updated

Part of situation: Celltrion biosimilar market expansion (2 clusters)

Celltrion posts record Q2 sales of 1.4 trillion won, driven by high‑margin biosimilars

Celltrion Q2 earnings biosimilars sales growth Samsung Biologics

Celltrion announced its second‑quarter 2025 results, reporting sales of 1.3937 trillion won and operating profit of 451.8 billion won, up 45 % and 86.3 % year‑on‑year respectively. The quarter yielded an operating margin of 32.4 % and a cost‑of‑sales ratio of 38 %, an improvement of 5.4 percentage points from the prior year.

The growth was powered by the company's newer biosimilar portfolio, which now makes up 65 % of total sales. Five recently launched products – Eydenzelt, Avtozma, Omlyclo, Stoboclo‑Osenvelt and Steqeyma – together generated more than 300 billion won, a 49 % increase from the previous quarter.

In the domestic market, Celltrion's Q2 revenue modestly outpaced rival Samsung Biologics, whose sales were 728 billion won lower, though Samsung Biologics posted a higher operating profit for the period.

Entities

Avtozma · Cardiol Therapeutics Inc. · CardiolRx · Celltrion · Eydenzelt · Omlyclo · Samsung Biologics

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

셀트리온, 2분기 역전…삼성바이오, 393억원 차로 상반기 왕좌 지켜 - 코메디닷컴 [kormedi.com]
about 1 month ago
셀트리온, 2분기 매출 1. 39조·영업익 4518억 역대 최대…영업이익률 32. 4% [biz.heraldcorp.com]
about 1 month ago
Celltrion sets fresh earnings record on newer biosimilars [www.koreaherald.com]
about 1 month ago